Literature DB >> 11124011

Secondary heat, but not mechanical, hyperalgesia induced by subcutaneous injection of bee venom in the conscious rat: effect of systemic MK-801, a non-competitive NMDA receptor antagonist.

H S Chen1, J Chen.   

Abstract

Subcutaneous (s.c.) administration of bee venom into the plantar surface of one hind paw in rats has been found to produce an immediate single phase of persistent spontaneous nociceptive responses (continuously flinching, licking or lifting the injected paw) for 1-2 h accompanied by a 72-96 hour period of primary heat and mechanical hyperalgesia in the injection site and a spread of heat, but not mechanical, hyperalgesia in the non-injected hind paw (Chen et al., 1999b). To gain insight into the underlying mechanisms of the bee venom-induced hyperalgesia in particular, we further identified a heat, but not mechanical, hyperalgesia in an area (paw pad) distant from the injection site induced by s.c. injection of bee venom into the posterior leg 0.8-1.2 cm proximal to the heel measured by paw withdrawal reflex to radiant heat or von Frey monofilament stimuli in conscious rats. In the bee venom-treated hind limb, however, significant reduction in both thermal latency and mechanical threshold of withdrawal reflex was identified for a period of more than 96 h in the heel with a similar characteristic to the primary heat and mechanical hyperalgesia identified in the injection site previously. The time course of the heat hyperalgesia identified in the paw pad of the bee venom-treated side was shorter and lasted for less than 48 h, which was in parallel with the reduction in thermal latency of the withdrawal reflex identified in the non-injected hind paw. Moreover, pre- or post-treatment with a single dose of MK-801 (0.01 mg/kg, i.p.), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, completely blocked the occurrence, and reversed the established process of the heat hyperalgesia identified in either the bee venom-treated or non-treated paw pads, while the same treatments with the drug did not produce any influence upon the development and maintaining of the heat and mechanical hyperalgesia identified in the heel of the injected hind limb. Taken together with our previous results following s.c. intraplantar bee venom injection, we conclude that: (1) in addition to the well-identified primary heat and mechanical hyperalgesia in the injection site and its adjacent area, s.c. bee venom is also able to produce a secondary heat hyperalgesia in a region distant from the injection site which has a similar characteristic to the contralateral heat hyperalgesia; (2) NMDA receptors are involved in either development or maintenance of the secondary and the contralateral heat hyperalgesia, but without any role in those processes of the primary heat and mechanical hyperalgesia; (3) the secondary heat hyperalgesia seen in the injected hind limb is likely to share the same neural mechanisms with that identified in the non-injected side via co-activation of NMDA receptors. Copyright 2000 European Federation of Chapters of the International Association for the Study of Pain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124011     DOI: 10.1053/eujp.2000.0197

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  11 in total

Review 1.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms.

Authors:  Kenneth E Miller; E Matthew Hoffman; Mathura Sutharshan; Ruben Schechter
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

Review 2.  Melittin, the Major Pain-Producing Substance of Bee Venom.

Authors:  Jun Chen; Su-Min Guan; Wei Sun; Han Fu
Journal:  Neurosci Bull       Date:  2016-03-17       Impact factor: 5.203

3.  Involvement of Rac1 signalling pathway in the development and maintenance of acute inflammatory pain induced by bee venom injection.

Authors:  Yan Wang; Yun-Fei Lu; Chun-Li Li; Wei Sun; Zhen Li; Rui-Rui Wang; Ting He; Fan Yang; Yan Yang; Xiao-Liang Wang; Su-Min Guan; Jun Chen
Journal:  Br J Pharmacol       Date:  2016-02-10       Impact factor: 8.739

Review 4.  The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword.

Authors:  Jun Chen; William R Lariviere
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

Review 5.  Roles of the hippocampal formation in pain information processing.

Authors:  Ming-Gang Liu; Jun Chen
Journal:  Neurosci Bull       Date:  2009-10       Impact factor: 5.203

6.  Roles of peripheral P2X and P2Y receptors in the development of melittin-induced nociception and hypersensitivity.

Authors:  Zhuo-Min Lu; Fang Xie; Han Fu; Ming-Gang Liu; Fa-Le Cao; Jian Hao; Jun Chen
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

7.  Synaptic Homeostasis and Allostasis in the Dentate Gyrus Caused by Inflammatory and Neuropathic Pain Conditions.

Authors:  Rui-Rui Wang; Yan Wang; Su-Min Guan; Zhen Li; Saurabh Kokane; Fa-Le Cao; Wei Sun; Chun-Li Li; Ting He; Yan Yang; Qing Lin; Jun Chen
Journal:  Front Synaptic Neurosci       Date:  2018-01-31

8.  Region- or state-related differences in expression and activation of extracellular signal-regulated kinases (ERKs) in naïve and pain-experiencing rats.

Authors:  She-Wei Guo; Ming-Gang Liu; Ya-Li Long; Li-Ying Ren; Zhuo-Min Lu; Hou-You Yu; Jun-Feng Hou; Hua Li; Cui-Ying Gao; Xiu-Yu Cui; Yang-Yuan An; Junfa Li; Lan-Feng Zhao; Jun Chen
Journal:  BMC Neurosci       Date:  2007-07-24       Impact factor: 3.288

9.  Non-Hebbian plasticity at C-fiber synapses in rat spinal cord lamina I neurons.

Authors:  Asami Naka; Doris Gruber-Schoffnegger; Jürgen Sandkühler
Journal:  Pain       Date:  2013-04-08       Impact factor: 6.961

10.  Objective validation of central sensitization in the rat UVB and heat rekindling model.

Authors:  N S Weerasinghe; B M Lumb; R Apps; S Koutsikou; J C Murrell
Journal:  Eur J Pain       Date:  2014-03-03       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.